Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs
| Autor: | A J Mitus, Mark A. Goldberg, Cynthia J. Rutherford, CJ McGarigle, Joseph H. Antin |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Chemotherapy
business.industry medicine.medical_treatment Hematopoietic growth factor Immunology Cell Biology Hematology Biochemistry Haematopoiesis surgical procedures operative medicine.anatomical_structure Erythropoietin Concomitant medicine Homologous chromosome Erythropoiesis Bone marrow business medicine.drug |
| Zdroj: | Blood. 83:1952-1957 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v83.7.1952.bloodjournal8371952 |
| Popis: | In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusion, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count > or = 10(4)/microL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|